{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:56:18Z","timestamp":1791860178833,"version":"4.3.4"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.pharep.2017.01.030","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T11:30:54Z","timestamp":1486035054000},"page":"595-601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant"],"prefix":"10.1007","volume":"69","author":[{"given":"Magdalena","family":"Sowa-Ku\u0107ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Pa\u0144czyszyn-Trzewik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina","family":"Misztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142 R.","family":"Jaeschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Sendek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Stycze\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Datka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Koperny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2017.01.030_bib0005","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1017\/S2045796015000542","article-title":"Heterogeneity in the prognosis of major depression: from the common cold to a highly debilitating and recurrent illness","volume":"24","author":"Lorenzo-Luaces","year":"2015","journal-title":"Epidemiol Psychiatr Sci"},{"key":"10.1016\/j.pharep.2017.01.030_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/0269881115609072","article-title":"The serotonergic system in the neurobiology of depression: relevance for novel antidepressants","volume":"30","author":"Kohler","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0015","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1177\/0269881114553252","article-title":"Antidepressant drug development: focus on triple monoamine reuptake inhibition","volume":"29","author":"Lane","year":"2015","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0020","series-title":"Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice","first-page":"9","article-title":"The philosophy of evidence-based medicine","author":"Guyatt","year":"2008"},{"key":"10.1016\/j.pharep.2017.01.030_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.pharmthera.2014.07.001","article-title":"Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data","volume":"145","author":"Sanchez","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharep.2017.01.030_bib0030","first-page":"36","article-title":"Vortioxetine (brintellix): a new serotonergic antidepressant","volume":"40","author":"D'Agostino","year":"2015","journal-title":"P T"},{"key":"10.1016\/j.pharep.2017.01.030_bib0035","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharep.2017.01.030_bib0040","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40263-014-0195-x","article-title":"Vortioxetine a review of its use in major depressive disorder","volume":"28","author":"Garnock-Jones","year":"2014","journal-title":"CNS Drugs"},{"issue":"Suppl. (13)","key":"10.1016\/j.pharep.2017.01.030_bib0045","first-page":"5","article-title":"Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance","volume":"64","author":"Richelson","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pharep.2017.01.030_bib0050","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.111.189068","article-title":"Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder","volume":"340","author":"Mork","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2017.01.030_bib0055","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0006-3223(02)01643-8","article-title":"Is there a role for 5-HT1A agonists in the treatment of depression","volume":"53","author":"Blier","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pharep.2017.01.030_bib0060","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharep.2017.01.030_bib0065","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/jpet.107.119404","article-title":"Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents","volume":"321","author":"Bonaventure","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharep.2017.01.030_bib0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/1568007043482624","article-title":"5-HT3 receptors","volume":"3","author":"Costall","year":"2004","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.pharep.2017.01.030_bib0075","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/FBP.0b013e3282f3cfd4","article-title":"Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models","volume":"19","author":"Ramamoorthy","year":"2008","journal-title":"Behav Pharm"},{"key":"10.1016\/j.pharep.2017.01.030_bib0080","unstructured":"European Medicines Agency: BRINTELLIX (vortioxetine)\u00ae. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002717\/WC500159447.pdf. In: Agency EM, editor. 2013."},{"key":"10.1016\/j.pharep.2017.01.030_bib0085","unstructured":"Brintellix (vortioxetine hydrobromide tablets): US prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/204447s000lbl.pdf. In: Administration FDA, editor. 2013."},{"key":"10.1016\/j.pharep.2017.01.030_bib0090","unstructured":"Brintellix (TM). IDdb author IDDB MEETING REPORT 2009 Medicinal Chemistry \u2013 Fourth Anglo-Swedish Symposium (Part I). Lund, Sweden."},{"key":"10.1016\/j.pharep.2017.01.030_bib0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1742-7843.2012.00886.x","article-title":"The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers","volume":"111","author":"Areberg","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40265-013-0161-9","article-title":"Vortioxetine first global approval","volume":"74","author":"Gibb","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.pharep.2017.01.030_bib0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1742-7843.2011.00810.x","article-title":"Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects","volume":"110","author":"Areberg","year":"2012","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0110","unstructured":"Lundbeck. Takeda and Lundbeck announce FDA approval of Brintellix\u2122 (vortioxetine) for treatment of adults with major depressive disorder. Accessed from: http:\/\/investor.lundbeck.com\/releasedetail.cfm?releaseid=794050. 2013."},{"key":"10.1016\/j.pharep.2017.01.030_bib0115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/ijcp.12350","article-title":"Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant \u2013 what is the number needed to treat, number needed to harm and likelihood to be helped or harmed","volume":"68","author":"Citrome","year":"2014","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pharep.2017.01.030_bib0120","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40261-013-0117-6","article-title":"Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant","volume":"33","author":"Chen","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pharep.2017.01.030_bib0125","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1124\/dmd.111.040428","article-title":"Biosynthesis and identification of an N-oxide\/N-glucuronide metabolite and first synthesis of an N-O-glucuronide metabolite of Lu AA21004","volume":"39","author":"Uldam","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2017.01.030_bib0130","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1124\/dmd.112.044610","article-title":"Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004","volume":"40","author":"Hvenegaard","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharep.2017.01.030_bib0135","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/0269881116628440","article-title":"The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies","volume":"30","author":"Baldwin","year":"2016","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0140","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2147\/NDT.S39544","article-title":"New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder","volume":"10","author":"Katona","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.pharep.2017.01.030_bib0145","first-page":"210","article-title":"Drug interactions with vortioxetine, a new multimodal antidepressant","volume":"50","author":"Spina","year":"2015","journal-title":"Riv Psichiatr"},{"key":"10.1016\/j.pharep.2017.01.030_bib0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12916-016-0560-3","article-title":"Cognitive remission: a novel objective for the treatment of major depression?","volume":"14","author":"Bortolato","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.pharep.2017.01.030_bib0155","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.euroneuro.2012.04.006","article-title":"Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters\u2013a rat microdialysis and electrophysiology study","volume":"23","author":"Pehrson","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0160","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145712001058","article-title":"The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism","volume":"16","author":"Betry","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0165","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/0269881114543719","article-title":"Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus","volume":"28","author":"Dale","year":"2014","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0170","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00213-015-3870-9","article-title":"Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain","volume":"232","author":"El Mansari","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharep.2017.01.030_bib0175","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.neuropharm.2013.05.014","article-title":"Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice","volume":"73","author":"Guilloux","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharep.2017.01.030_bib0180","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.bbr.2013.09.002","article-title":"Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats","volume":"256","author":"Li","year":"2013","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pharep.2017.01.030_bib0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1124\/pr.111.005397","article-title":"The flinders sensitive line rat model of depression\u201325 years and still producing","volume":"65","author":"Overstreet","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharep.2017.01.030_bib0190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.pnpbp.2014.12.002","article-title":"Effect of the multimodal acting antidepressant vortioxetine on rat hippocampal plasticity and recognition memory","volume":"58","author":"Betry","year":"2015","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pharep.2017.01.030_bib0195","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.neuropharm.2014.10.015","article-title":"Involvement of 5-HT(7) receptors in vortioxetine's modulation of circadian rhythms and episodic memory in rodents","volume":"89","author":"Westrich","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharep.2017.01.030_bib0200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.euroneuro.2013.07.001","article-title":"Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism","volume":"24","author":"du Jardin","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0205","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.euroneuro.2013.10.011","article-title":"Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation","volume":"24","author":"Jensen","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pbb.2013.01.019","article-title":"Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats","volume":"105","author":"Mork","year":"2013","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharep.2017.01.030_bib0215","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1017\/S1461145714000571","article-title":"Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats","volume":"17","author":"Wallace","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0220","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.pbb.2015.05.013","article-title":"Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice","volume":"135","author":"Li","year":"2015","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharep.2017.01.030_bib0225","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00213-008-1132-9","article-title":"Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat-a back translational study","volume":"202","author":"Goetghebeur","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharep.2017.01.030_bib0230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/clpt.2013.39","article-title":"A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition","volume":"93","author":"Theunissen","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharep.2017.01.030_bib0235","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12888-014-0276-x","article-title":"Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials","volume":"14","author":"Berhan","year":"2014","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.pharep.2017.01.030_bib0240","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1503\/jpn.140120","article-title":"Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder","volume":"40","author":"Pae","year":"2015","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pharep.2017.01.030_bib0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13643-015-0001-y","article-title":"The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: a systematic review and meta-analysis","volume":"4","author":"Meeker","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.pharep.2017.01.030_bib0250","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00213-014-3633-z","article-title":"The efficacy and safety of 5mg\/d Vortioxetine compared to placebo for major depressive disorder: a meta-analysis","volume":"232","author":"Fu","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharep.2017.01.030_bib0255","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.euroneuro.2016.03.007","article-title":"A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults","volume":"26","author":"Thase","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0260","first-page":"2015","article-title":"The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of randomized clinical trials","author":"Rosenblat","year":"2015","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0265","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1185\/03007995.2014.969566","article-title":"Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies","volume":"30","author":"Llorca","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharep.2017.01.030_bib0270","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40261-016-0396-9","article-title":"Vortioxetine versus duloxetine in the treatment of patients with major depressive disorder: a meta-analysis of randomized controlled trials","volume":"36","author":"Li","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.pharep.2017.01.030_bib0275","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1185\/03007995.2015.1014028","article-title":"Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study","volume":"31","author":"Wang","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.pharep.2017.01.030_bib0280","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/hup.2424","volume":"29","author":"Montgomery","year":"2014","journal-title":"Hum Psychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0285","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.pharep.2017.01.030_bib0290","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jpsychires.2015.02.017","article-title":"Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis","volume":"64","author":"Pae","year":"2015","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pharep.2017.01.030_bib0295","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jad.2016.02.042","article-title":"Vortioxetine for major depressive disorder: an indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"196","author":"Citrome","year":"2016","journal-title":"J Affect Disord"},{"key":"10.1016\/j.pharep.2017.01.030_bib0300","series-title":"Technology appraisal guidance. Vortioxetine for treating major depressive episodes (TA367)","author":"NICE","year":"2015"},{"key":"10.1016\/j.pharep.2017.01.030_bib0305","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2147\/NDT.S104050","article-title":"The efficacy and safety of multiple doses of vortioxetine for generalized anxiety disorder: a meta-analysis","volume":"12","author":"Fu","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.pharep.2017.01.030_bib0310","unstructured":"FDA Drug Safety Communication: FDA approves brand name change for antidepressant drug Brintellix (vortioxetine) to avoid confusion with antiplatelet drug Brilinta (ticagrelor) http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm497942.htm."}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016303619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114016303619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:55Z","timestamp":1752611815000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2017.01.030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1734114016303619"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2017.01.030","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2017.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}